Niu Y, Sun W, Chen K, et al. - A scoring system based on expression profiles of pivotal autophagy-related (ATG) genes in stage III/IV ovarian cancer patients who received chemotherapy was developed and validated. Training dataset comprised data of ovarian serous cystadenocarcinoma in The Cancer Genome Atlas (TCGA-OV). Patients in a Chinese local database and a dataset from the Gene Expression Omnibus were two validation datasets. Researchers selected 43 autophagy-related genes to develop the ATG score. In TCGA-OV, better overall survival and recurrence-free survival were observed among patients with lower ATG scores. After complete or partial remission to primary therapy, the low-score group displayed a recurrence rate of 47.2% and the high-score group displayed a recurrence rate of 68.3%. This novel scoring system accurately thus identified valuable for predicting the outcomes of advanced ovarian cancer patients after chemotherapy and hence may provide a promising tool for the development of personalized therapy in the future.